SPRC (SciSparc Ltd.) רווח נקי למניה אחת בשנים עשר החודשים האחרונים

SciSparc Ltd is burning capital on research without current sales, yet patent protection in the brain cannabinoid niche ensures high margins. The annual percentage change in EPS TTM clearly demonstrates the volatility of expectations, where 62.50 represents the current level of the metric. Business development relies on a team of top pharmacologists creating unique therapy methods for rare pathologies.
SPRC (scisparc.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים

The indicator is calculated as the percentage change in net income per share over the last twelve months relative to the same period last year. This metric reflects the actual profitability dynamics of the business and its ability to scale earnings. For SciSparc Ltd (SPRC), this growth confirms the commercialization of patents in CNS therapy. A positive trend in the annual percentage increase of EPS TTM signals market expansion, while a flattening of the curve may indicate a loss of competitive advantages.